Proactive Investors - Run By Investors For Investors

Axsome Therapeutics extends gains after raising $23.3M to fund late stage depression drug development

AXS-05, a key drug in Axsome’s pipeline, significantly improved symptoms of depression after six weeks in a trial evaluating 80 adults
A woman clutching her head
The New York-based biotech is developing novel therapies for central nervous system disorders

Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) extended gains in premarket trade Tuesday after the biopharmaceutical company announced that it raised $23.3 million to fund the ongoing clinical development of its late-stage drug candidates.

Shares of the New York-based biotech had soared Monday after the company unveiled rosy trial results for a drug that addresses depression.

AXS-05, a key drug in Axsome’s pipeline which consists of dextromethorpan and bupropion, significantly improved symptoms of depression in a trial evaluating 80 adults after six weeks compared to the anti-depressive bupropion on its own. The company said AXS-05 was safe and well tolerated with no serious adverse events.

READ: Axsome Therapeutics soars after unveiling rosy trial results for depression drug

The results were met with enthusiasm by investors who sent Axsome shares up nearly 167% on Monday afternoon. Shares were up again nearly 17.8% to $8.09 in premarket trade Tuesday.

The biotech said it raised approximately $23.3 million through the sale of 2,881,066 shares under its existing at-the-market (ATM) facility with Leerink Partners LLC.

Axsome said it intends to use the proceeds from the offering to “continue to fund the ongoing clinical development of its late stage product candidates.”

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full AXSM profile View Profile

Axsome Therapeutics Inc Timeline

Related Articles

Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product
Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use